Medtronic Receives FDA Approval for First and Only Pacemaker System in the U.S. Designed for Use in the MRI Environment

MINNEAPOLIS – February 8, 2011 – Medtronic, Inc. (NYSE: MDT) today announced that the U.S. Food and Drug Administration (FDA) approved its Revo MRI™ SureScan® pacing system, the first and only pacemaker in the U.S. specifically designed for use in an Magnetic Resonance Imaging (MRI) environment and approved as MR-Conditional. Shipments of Revo MRI will begin immediately.

Until now, MRI